Spravato™ Treatment

What is SPRAVATO™ ?

Indications:

SPRAVATO™ (esketamine) CIII Nasal Spray is indicated, in conjunction with an oral antidepressant, for the treatment of:

• Treatment Resistant Depression (TRD) in adults.
• Depressive symptoms in adults with Major Depressive Disorder (MDD) with acute suicidal ideation or behavior.

SPRAVATO™ is available only through a restricted program called the SPRAVATO™ REMS (Risk Evaluation and Mitigation Strategy) because of the risks of serious adverse outcomes from sedation, dissociation, and abuse and misuse.

To learn more: